SEOM clinical guidelines for cervical cancer (2019)
Open Access
- 24 January 2020
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 22 (2) , 270-278
Abstract
Cervical cancer (CC) is the fourth most common cancer in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income countries, the screening programs have dramatically decreased the incidence of CC; however, the lack of accessibility to them in developing countries makes CC an important cause of mortality. Clinical stage is the most relevant prognostic factor in CC. The new FIGO staging system published in 2018 is more accurate than the previous one since it takes into account the lymph node status. In early stages, the primary treatment is surgery—with some concerns recently raised regarding minimally invasive surgery because it might decrease survival—or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. For recurrent or metastatic CC, the combination of chemotherapy plus bevacizumab is the preferred therapy. Immunotherapy approach based on checkpoint inhibitors is evolving as the election therapy following failure to platinum therapy.Keywords
This publication has 30 references indexed in Scilit:
- The sentinel node procedure in early stage cervical cancer, taking the next step; a diagnostic reviewGynecologic Oncology, 2015
- Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic reviewEuropean Journal of Surgical Oncology, 2015
- Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505Journal of Clinical Oncology, 2015
- Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trialsThe Lancet, 2014
- Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancerNuclear Medicine Communications, 2014
- Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancerCochrane Database of Systematic Reviews, 2013
- Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the CervixJournal of Clinical Oncology, 2011
- Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysisCochrane Database of Systematic Reviews, 2010
- A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: Follow-up of a gynecologic oncology group studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- FDG-PET for management of cervical and ovarian cancerGynecologic Oncology, 2005